文献速递毛发、甲与色素性疾病

白癜风核心结局(域)集是否已落实?对白癜风随机临床试验中结局与结局测量指标的更新系统综述

Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials.
PubMed 文献 · Br J Dermatol · 2023-01-01

该更新系统综述检索2009年11月至2021年3月数据库,纳入174项白癜风随机临床试验,评估2015年国际共识核心结局域集的采用情况。结果显示仅10%(11/112)的2016-2021年试验报告了全部三个核心结局域,无试验报告全部核心与推荐结局域;再色素化测量工具达49种,结局报告与共识推荐间仍存在差距。

要点

  • 再色素化是89%(150/169)试验的主要结局,但测量工具多达49种。
  • 副作用/危害在78%(136/174)试验中报告,维持再色素化仅11%(20/174)报告。
  • 2016-2021年试验中仅10%(11/112)报告全部三个核心结局域,无试验报告全部核心与推荐域。

核心结论

  • 缩小共识推荐与随机临床试验结局报告之间的差距仍需努力。

研究设计与样本

  • 更新系统综述,检索PubMed、Cochrane Library(CENTRAL与Systematic Reviews)及ClinicalTrials.gov,纳入2009年11月至2021年3月的白癜风随机临床试验,由两名研究者独立筛选与提取数据。

主要发现

  • 共纳入174项随机临床试验,其中62项发表于2009年至2015年,112项发表于2016年至2021年。
  • 共报告38种不同结局;再色素化为89%(150/169)试验的主要结局,测量再色素化使用49种不同工具。
  • 副作用/危害在78%(136/174)试验中报告;维持已获再色素化仅在11%(20/174)试验中报告,随访时长从1个月到14个月不等。
  • 美容可接受性与疾病活动停止仅在2%(4/174)试验中评估;生活质量在13%(22/174)试验中评估。
  • 2016年至2021年发表的112项随机临床试验中,仅11项(10%)报告了全部三个核心结局域(再色素化、副作用/危害与维持已获再色素化),无试验报告全部核心与推荐结局域。

关键数值与推荐

  • 2015年国际共识核心结局域集确定三个核心结局域:再色素化、副作用/危害与维持已获再色素化;另推荐纳入四个条目。
  • 推荐再色素化通过四分位数(0-25%、26-50%、51-79%、80-100%)测量再色素化百分比,并使用Vitiligo Noticeability Scale评估结果的美容可接受性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2015, a major achievement in vitiligo research was the development of an internationally agreed upon core outcome domain set for randomized clinical trials (RCTs). Three outcomes were identified as being essential: repigmentation, side-effects/harms and maintenance of gained repigmentation. Four items were further recommended for inclusion. The following recommendations then followed: repigmentation should be assessed by measuring the percentage of repigmentation in quartiles (0-25%, 26-50%, 51-79%, 80-100%) and cosmetic acceptability of the results should be assessed using the Vitiligo Noticeability Scale. OBJECTIVES: The primary objective of this study was to assess uptake of the core outcome domain set for RCTs in vitiligo. Secondary objectives were to update the systematic review on outcomes reported in vitiligo RCTs, and to assess whether repigmentation and cosmetic acceptability of the results were measured using the above-mentioned recommended scales. METHODS: We searched PubMed, Cochrane Library (CENTRAL and Systematic Reviews) and ClinicalTrials.gov for vitiligo RCTs between November 2009 and March 2021. Screening and data extraction were independently performed on title and summary by two researchers. All outcomes and outcome measures reported in eligible RCTs were retrieved and collated. RESULTS: In total, 174 RCTs were identified: 62 were published between 2009 and 2015, and 112 were published between 2016 and 2021.Thirty-eight different outcomes were reported. Repigmentation was the primary outcome in 89% of trials (150 of 169). Forty-nine different tools were used to measure repigmentation. Side-effects and harms were reported in 78% of trials (136 of 174). Maintenance of gained repigmentation was reported in only 11% of trials (20 of 174) and duration of follow-up varied greatly from 1 to 14 months. Cosmetic acceptability of the results and cessation of disease activity were assessed in only 2% of trials (four of 174). Quality of life of patients with vitiligo was assessed in 13% of trials (22 of 174). Finally, only 11 of 112 RCTs (10%) published between 2016 and 2021 reported all three essential core outcome domains (repigmentation, side-effects and maintenance of gained repigmentation) and none of the trials reported both essential and recommended core outcome domains. CONCLUSIONS: Efforts are still needed to close the gap between set recommendations and RCT outcome reporting.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Eleftheriadou V, Bergqvist C, Kechichian E, et al. Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials. Br J Dermatol. 2023. PMID: 36763863. doi:10.1093/bjd/ljac074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。